Abbott Laboratories (ABT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Abbott Laboratories (ABT) Healthcare & Pipeline Overview

Abbott Laboratories, a diversified healthcare leader with a $202B market cap, develops and markets established pharmaceuticals, diagnostics, nutritional products, and medical devices globally. With a strong focus on innovation and a 13.9% profit margin, Abbott serves diverse patient needs across multiple healthcare segments, maintaining a 2.89% dividend yield.

What Is the Investment Thesis for ABT?

Abbott Laboratories presents a compelling investment case driven by its diversified healthcare portfolio and consistent financial performance. With a market capitalization of $202B and a P/E ratio of 23.8, Abbott demonstrates stability and growth potential. The company's 13.9% profit margin and 56.4% gross margin reflect efficient operations and strong pricing power. A key value driver is Abbott's ability to innovate and introduce new products across its four segments. Upcoming catalysts include the expansion of its medical device offerings and continued growth in emerging markets. However, potential risks include regulatory challenges and competition from other major healthcare players such as UnitedHealth Group Incorporated and Novartis AG. Abbott's 2.89% dividend yield provides an additional incentive for investors.

Based on FMP financials and quantitative analysis

ABT Key Highlights

Market Cap of $202B reflects Abbott's significant presence and stability in the healthcare industry.

• P/E Ratio of 23.8 indicates investor confidence in Abbott's earnings potential compared to the industry average.
• Profit Margin of 13.9% demonstrates Abbott's ability to generate profits efficiently from its diverse product portfolio.
• Gross Margin of 56.4% showcases Abbott's strong pricing power and cost management in manufacturing and selling healthcare products.
• Dividend Yield of 2.89% provides a steady income stream for investors, highlighting Abbott's commitment to shareholder returns.

Who Are ABT's Competitors?

ABT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ABT's Key Strengths?

Diversified product portfolio reduces reliance on any single product or market.

• Strong global presence with operations in numerous countries.
• Consistent investment in research and development drives innovation.
• Established brand reputation and customer loyalty.

What Are ABT's Weaknesses?

Exposure to generic competition for established pharmaceutical products.

• Dependence on regulatory approvals for new products.
• Potential for product recalls and liability claims.
• Currency exchange rate fluctuations can impact financial results.

What Could Drive ABT Stock Higher?

ABT catalyst: New product launches in the medical device segment are expected to drive revenue growth in the next 12-18 months.

• Expansion into emerging markets, particularly in Asia and Latin America, is expected to contribute to long-term growth.
• Continued investment in research and development is expected to yield innovative products and technologies.
• Regulatory approvals for new diagnostic solutions are anticipated in the next 6-12 months.

What Are the Key Risks for ABT?

Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 8 reported quarters.

• Increased competition from other healthcare companies could impact market share and profitability.
• Changes in healthcare regulations and reimbursement policies could affect revenue and earnings.
• Economic downturns could reduce healthcare spending and impact sales.
• Patent expirations could lead to loss of exclusivity and increased generic competition.
• Product recalls or safety concerns could damage Abbott's reputation and result in liability claims.

What Are the Growth Opportunities for ABT?

• Expansion of Medical Device Portfolio: Abbott has significant growth opportunities in expanding its medical device portfolio, particularly in areas such as cardiovascular devices and diabetes care. The global market for cardiovascular devices is expected to reach $65 billion by 2028. By investing in research and development and strategic acquisitions, Abbott can introduce innovative products that address unmet clinical needs and capture a larger share of this growing market. This includes advancements in minimally invasive surgical techniques and remote monitoring technologies.
• Emerging Markets Penetration: Abbott can drive growth by further penetrating emerging markets, where healthcare spending is increasing rapidly. Countries like China and India offer significant opportunities for Abbott to expand its sales of established pharmaceuticals, diagnostics, nutritional products, and medical devices. Tailoring products to meet the specific needs of these markets and establishing strong distribution networks are critical for success. The emerging markets healthcare sector is projected to grow at a rate of 8-10% annually.
• Advancements in Diagnostic Technologies: Abbott is well-positioned to capitalize on advancements in diagnostic technologies, particularly in the areas of molecular diagnostics and point-of-care testing. The global molecular diagnostics market is expected to reach $14 billion by 2027. By developing innovative diagnostic solutions that enable faster and more accurate detection of diseases, Abbott can improve patient outcomes and drive revenue growth. This includes developing tests for infectious diseases, cancer, and genetic disorders.
• Nutritional Products Innovation: Abbott has opportunities to innovate in its nutritional products segment by developing products that address specific health needs, such as infant nutrition, sports nutrition, and medical nutrition. By investing in research and development and collaborating with healthcare professionals, Abbott can create products that meet the evolving needs of consumers and patients. This includes developing products with enhanced nutritional profiles and improved taste and texture.
• Strategic Partnerships and Acquisitions: Abbott can accelerate its growth by pursuing strategic partnerships and acquisitions that complement its existing product portfolio and expand its geographic reach. By partnering with other healthcare companies and acquiring innovative technologies, Abbott can enhance its competitive position and drive revenue growth. This includes partnering with companies that specialize in digital health solutions and acquiring companies that have strong market positions in emerging markets.

What Are ABT's Competitive Advantages?

• Diversified product portfolio across multiple healthcare segments.
• Strong brand reputation and customer loyalty.
• Extensive global distribution network.
• Significant investment in research and development.
• Regulatory expertise and compliance.

What Does ABT Do?

Founded in 1888 in North Chicago, Illinois, Abbott Laboratories has evolved from a small pharmaceutical preparation firm into a global healthcare leader. Initially focused on developing standardized medications, Abbott has expanded its portfolio to include a wide array of products across four key segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals addressing various conditions, including pancreatic exocrine insufficiency and hypertension. The Diagnostic Products segment offers advanced laboratory systems and molecular diagnostics. The Nutritional Products segment provides pediatric and adult nutritional solutions. The Medical Devices segment develops devices for cardiovascular diseases, diabetes care, and neuromodulation. Abbott's global presence spans numerous countries, with a significant footprint in both developed and emerging markets. The company's commitment to research and development has resulted in innovative products that address unmet medical needs and improve patient outcomes. Abbott's strategic acquisitions and partnerships have further strengthened its market position and expanded its product offerings. With a workforce of 114,000 employees, Abbott continues to focus on delivering high-quality healthcare solutions to patients worldwide.

What Products and Services Does ABT Offer?

• Develops and manufactures a wide range of healthcare products.
• Offers established pharmaceutical products for various medical conditions.
• Provides diagnostic products, including laboratory systems and molecular diagnostics.
• Manufactures and sells nutritional products for pediatric and adult use.
• Offers medical devices for cardiovascular diseases, diabetes care, and neuromodulation.
• Provides point-of-care testing solutions for rapid diagnostics.
• Offers informatics and automation solutions for laboratories.

How Does ABT Make Money?

• Develops and manufactures healthcare products across four segments.
• Sells products through a global distribution network to healthcare providers and consumers.
• Invests in research and development to innovate new products and improve existing ones.
• Generates revenue through product sales and licensing agreements.

What Industry Does ABT Operate In?

Abbott Laboratories operates in the dynamic and competitive healthcare industry, which is characterized by continuous innovation, stringent regulations, and evolving patient needs. The global medical devices market is projected to reach $600 billion by 2026, driven by technological advancements and an aging population. Abbott competes with major players like UnitedHealth Group Incorporated and Novartis AG, focusing on differentiated products and strategic partnerships to maintain its market share. The industry is also influenced by trends such as personalized medicine, digital health, and value-based care, requiring companies to adapt and invest in new technologies to stay competitive.

Who Are ABT's Key Customers?

• Hospitals and clinics
• Diagnostic laboratories
• Pharmacies
• Retail consumers
• Healthcare professionals

Over the past six months, Abbott Laboratories insiders filed 29 SEC Form 4 transactions — 4 sales and 25 purchases. On net that is roughly 66K shares acquired (about $3.3M) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Abbott Laboratories

Revenue for Abbott Laboratories came in at $12.59B during Q2 2026, a 12.8% improvement versus the preceding quarter. The company recorded net income of $928.0M, with diluted EPS of $0.53. Quarter-over-quarter revenue has been mixed, typical for a mega-cap company operating in Healthcare. Across the four most recent quarters, ABT averaged $0.78 in diluted EPS.

ABT Valuation & Market Position

With a $202B market cap, Abbott Laboratories sits in the mega-cap segment of the market. Relative to its peer group, ABT's quantitative score of 70/100 is roughly in line with the peer average of 64/100.

Return on equity for Abbott Laboratories stands at 12.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.7%, showing how much profit it generates from its asset base. ABT trades at a trailing price-to-earnings ratio of 23.82, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 4.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.39 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.2%, the inverse of the P/E and a quick read on earnings relative to price.

Abbott Laboratories's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.48 places it in the safe zone, indicating low near-term bankruptcy risk.

Abbott Laboratories has missed Wall Street's EPS estimate in 0 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 0.7% above estimates on average.

Wall Street analysts project Abbott Laboratories revenue of about $50.31B for fiscal 2026, with EPS near $5.52. The estimate reflects 20 contributing analysts.

Company Profile

Abbott Laboratories operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in North Chicago, US. The company is led by CEO Robert Ford. ABT has traded publicly since 1980.

ABT Financials

ABT earnings history & estimates →

ABT Latest News

ABT Analyst Consensus

ABT MoonshotScore

Latest Abbott Laboratories Analysis

What Investors Ask About Abbott Laboratories (ABT) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources